Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AMRX 
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: AMRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.5
1 Year Target Price $13.5
| 1 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 7.63% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.56B USD | Price to earnings Ratio 1135 | 1Y Target Price 13.5 |
Price to earnings Ratio 1135 | 1Y Target Price 13.5 | ||
Volume (30-day avg) 4 | Beta 1.38 | 52 Weeks Range 6.68 - 11.73 | Updated Date 11/4/2025 |
52 Weeks Range 6.68 - 11.73 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-07 | When - | Estimate 0.1567 | Actual 0.17 |
Profitability
Profit Margin 0.2% | Operating Margin (TTM) 12.16% |
Management Effectiveness
Return on Assets (TTM) 6.84% | Return on Equity (TTM) -881.26% |
Valuation
Trailing PE 1135 | Forward PE 6.3 | Enterprise Value 5776773813 | Price to Sales(TTM) 1.21 |
Enterprise Value 5776773813 | Price to Sales(TTM) 1.21 | ||
Enterprise Value to Revenue 2.02 | Enterprise Value to EBITDA 9.89 | Shares Outstanding 314079309 | Shares Floating 190938744 |
Shares Outstanding 314079309 | Shares Floating 190938744 | ||
Percent Insiders 46.48 | Percent Institutions 46.85 |
Upturn AI SWOT
Amneal Pharmaceuticals, Inc. Class A Common Stock
Company Overview
History and Background
Amneal Pharmaceuticals, Inc. was founded in 2002 by Chirag and Chintu Patel. It is a generics and specialty pharmaceutical company. Amneal has grown significantly through acquisitions and organic growth, becoming a major player in the generic drug market.
Core Business Areas
- Generics: Develops, manufactures, and distributes a wide range of generic pharmaceutical products across various therapeutic areas.
- Specialty: Focuses on developing and marketing branded specialty pharmaceutical products, including central nervous system (CNS) and endocrinology products.
- Injectables: Develops and manufactures injectable drugs, catering to hospital and clinical settings.
Leadership and Structure
The leadership team includes Chirag Patel (Co-CEO), Chintu Patel (Co-CEO), and Tasos Baikas (CFO). Amneal has a hierarchical organizational structure with distinct departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Levothyroxine Sodium: A generic medication used to treat hypothyroidism. Market share data unavailable. Competitors include Mylan (now Viatris), Teva Pharmaceutical Industries, and Sandoz.
- Lorazepam: A generic benzodiazepine medication used to treat anxiety disorders. Market share data unavailable. Competitors include Mylan (now Viatris), Teva Pharmaceutical Industries, and Sandoz.
- Rytary: A branded specialty product for Parkinson's disease. Market share data unavailable. Competitors include AbbVie (Sinemet), and various generic versions.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with increasing pressure on generic drug prices. The demand for affordable medications drives generic market growth.
Positioning
Amneal is a significant player in the generic pharmaceutical market, leveraging its broad product portfolio and manufacturing capabilities. It has a competitive advantage in select therapeutic areas, but faces price pressures.
Total Addressable Market (TAM)
The global generic drug market is estimated to be over $400 billion. Amneal's position is around 0.1-0.2% of the total addressable market. They are focused on growing their market share through product launches and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong manufacturing capabilities
- Established distribution network
- Experienced management team
- Focus on complex generics
Weaknesses
- High debt levels
- Dependence on generic drug market
- Exposure to price erosion
- History of compliance issues
- Limited presence in high-growth specialty areas
Opportunities
- Expansion into biosimilars
- Strategic acquisitions and partnerships
- Growth in emerging markets
- New product launches
- Increase in chronic diseases requiring medication
Threats
- Increasing competition from other generic manufacturers
- Price erosion due to intense competition
- Regulatory changes and compliance challenges
- Intellectual property disputes
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- Sandoz (Novartis - NVS)
Competitive Landscape
Amneal faces intense competition from larger generic manufacturers with broader product portfolios and greater financial resources. Amneal's focus on complex generics and strategic acquisitions are key differentiators.
Major Acquisitions
AvKARE
- Year: 2022
- Acquisition Price (USD millions): 185
- Strategic Rationale: Expanded Amneal's institutional business and product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Amneal's historical growth has been driven by acquisitions and generic drug launches. However, price erosion has impacted profitability.
Future Projections: Future growth is expected to come from new product launches, expansion into biosimilars, and strategic partnerships. Analyst estimates unavailable.
Recent Initiatives: Recent initiatives include focusing on complex generics, restructuring debt, and improving operational efficiency.
Summary
Amneal Pharmaceuticals is a generics and specialty pharmaceutical company facing challenges due to price erosion and high debt levels. The company is focusing on new product launches, strategic acquisitions, and operational efficiencies to improve its financial performance. Its strength lies in its diversified product portfolio and manufacturing capabilities. However, the company needs to manage its debt and navigate the competitive generic drug market effectively to achieve sustainable growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry reports
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary depending on the source. Financial data should be verified with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Exchange NYSE | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2009-01-15 | Co-Founder, Co-CEO, President & Director Mr. Chirag K. Patel | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8300 | Website https://www.amneal.com |
Full time employees 8300 | Website https://www.amneal.com | ||
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.